At the heart of SHRO’s mission to conquer cancer lies a global network of state-of-the-art laboratories, where innovation meets action. In an era defined by rapid technological advancements and the transformative potential of artificial intelligence (AI), owning and operating cutting-edge research facilities is not just an advantage-it’s a necessity.
Our laboratories in Turin, Siena (Italy), and Philadelphia (USA) are more than physical spaces; they are engines of discovery, strategically positioned to accelerate breakthroughs in oncology.
Global Hubs
Turin, Italy | Philadelphia, USA | Siena, Italy
SHRO’s laboratories are embedded within some of the world’s most prestigious academic and research institutions. In Philadelphia, our flagship facility resides at the Temple University – College of Science and Technology, a nexus for interdisciplinary collaboration. Meanwhile, our laboratories in Siena operate in partnership with the University of Siena, bridging centuries of academic tradition with futuristic research. Soon, a new, expansive laboratory in central Philadelphia will join this network, further amplifying our capacity to innovate.
By owning these facilities, we maintain complete autonomy over their design, technology, and operations ensuring agility in adopting emerging tools and methodologies. This control is critical in a field where even minor delays can cost lives.
Labs in USA
Philadelphia
- Temple University College of Science and Technology, 1900 N 12th Street Philadelphia, PA 19122
- Race Street Expansion: Our newest investment, a 15,000-sq-ft laboratory in central Philadelphia, will pioneer:
- AI-Driven Drug Design: Utilizing machine learning to predict compound efficacy.
- Nanomedicine Development: Engineering targeted drug delivery systems.
- Collaborative Spaces: Open-plan labs designed for cross-disciplinary teamwork with startups and biotech firms.
Labs in Italy
Turin
- Focus: Molecular oncology and biomarker discovery.
- Partnerships: Embedded within academic networks, including the University of Turin, to leverage Italy’s expertise in genetic research.
Siena
- Focus: Translational research bridging lab findings to clinical trials.
- Collaboration: Joint projects with the Azienda Ospedaliera Universitaria Senese to test therapies in real-world patient cohorts.
Campania, Naples and Mercogliano
- Partnerships:
- University of Naples Federico II: Collaborative focus on precision medicine and targeted therapies, leveraging Naples’ expertise in cancer genomics.
- Luigi Vanvitelli University of Caserta: Joint projects on clinical trial optimization and cancer epidemiology, particularly in Southern Italy’s patient populations.
- Impact: These labs serve as critical nodes for addressing Mediterranean-specific cancer disparities (e.g., BRCA mutations, gastric cancers) while fostering talent through SHRO’s mobility programs.